Core Viewpoint - InnoCare Pharma-B (09606) has seen a significant stock price increase, rising over 13% during trading, with a current price of 314.4 HKD and a trading volume of 573 million HKD. The company announced plans to list on the STAR Market, pending market conditions and necessary approvals [1]. Group 1: Company Developments - The board of InnoCare Pharma has resolved to pursue a listing on the STAR Market, which requires further approval from the board, shareholders, and regulatory authorities [1]. - InnoCare Pharma's IPO on the Hong Kong Stock Exchange raised over 1.5 billion HKD, marking it as one of the largest IPOs in the Hong Kong 18A sector in the past four years [1]. Group 2: Industry Insights - According to Guojin Securities, the rapid innovation in the ADC technology sector has led to significant transactions, with InnoCare Pharma establishing multiple licensing and collaboration agreements with leading global companies, including BioNTech, BeiGene, Adcendo, GSK, and Avenzo [1]. - The confirmed business development (BD) revenue for InnoCare Pharma is projected to be 1.781 billion, 1.937 billion, and 1.227 billion CNY for the first halves of 2023, 2024, and 2025, respectively, with a total transaction value exceeding 6 billion USD [1].
港股异动 | 映恩生物-B(09606)盘中涨超13% 近期宣布拟在科创板上市 公司BD总交易超60亿美元